Antihyperuricemic Effect of <i>Dendropanax morbifera</i> Leaf Extract in Rodent Models

Lee, Dongho; Kim, Jin-Kyoung; Han, Yongjae; Park, Kwang Il

doi:https://doi.org/10.1155/2021/3732317

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion Data Availability Conflicts of Interest Authors’ Contributions References Copyright Related Articles

Research Article | Open Access

Volume 2021 | Article ID 3732317 | https://doi.org/10.1155/2021/3732317

Antihyperuricemic Effect of Dendropanax morbifera Leaf Extract in Rodent Models

Dongho Lee,¹Jin-Kyoung Kim,^2,3Yongjae Han,¹and Kwang Il Park⁴

Academic Editor: Slim Smaoui

Received06 May 2021

Revised08 Jul 2021

Accepted16 Jul 2021

Published23 Jul 2021

Abstract

Dendropanax morbifera is a well-known traditional medicine used in China and Korea to treat intestinal disorders, urosis, diuresis, and chronic glomerulonephritis. Hyperuricemia is a metabolic disorder characterized by a high uric acid level in serum due to an imbalance between uric acid production and excretion and causes gout. Recently, the prevalence of hyperuricemia worldwide has been continuously increasing. Xanthine oxidase (XOD) inhibitors (allopurinol (ALP) and febuxostat) and uricosuric agents (benzbromarone and probenecid) are used to treat hyperuricemia clinically. However, because these drugs are poorly tolerated and cause side effects, such as kidney diseases, hepatotoxicity, gastrointestinal symptoms, and hypersensitivity syndrome, only a limited number of drugs are available. We investigated the antihyperuricemic effects of Dendropanax morbifera leaf ethanol extract (DMLE) and its underlying mechanisms of action through in vitro and in vivo studies. We evaluated uric acid levels in serum and urine, and xanthine oxidase (XOD) inhibition activity in the serum and liver tissue of a hyperuricemic rat model of potassium oxonate (PO)-induced hyperuricemic rats. In vitro study, XOD-inhibitory activity was the lowest among the test substances at the IC50 of ALP. However, the IC50 of DMLE-70 was significantly low compared with that of other DMLEs (). In PO-induced hyperuricemic rats, uric acid (UA) levels in serum and urine were significantly reduced in all DMLE-70 and allopurinol-treated (ALT) groups than in the PC group (). UA levels in urine were lower than those in serum in all DME groups. In PO-induced hyperuricemic rats, DMEE-200 reduced UA concentration in serum and increased UA excretion in the urine. These findings suggest that DMLE exerts antihyperuricemic and uricosuric effects on promoting UA excretion by enhanced secretion and inhibition of UA reabsorption in the kidneys. Thus, DMLE may be a potential treatment for hyperuricemia and gout.

1. Introduction

Hyperuricemia means elevated uric acid (UA) level (more than 6.8 mg/dL) in the blood [1]. The disease is associated with a significantly increased risk of gout, cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus [2]. Serum UA (SUA) is the final product of purine metabolism [3]. Approximately two-thirds of SUA is produced from internal metabolic processes, and the rest is due to a high-purine diet [4]. Approximately 60%–70% of UA from the body is excreted through the kidneys, and the remaining is secreted in biliary secretions and the intestine. It is then further metabolized by gut bacteria in uricolysis [5]. Abnormal UA metabolism and decreased excretion by the kidneys are among the major causes of hyperuricemia [6].

Globally, hyperuricemia prevalence appears to be increasing as it is diagnosed in 5%–30% of the general population [7, 8]. It is also higher in men living in developed countries than women [9]. In the United States, the hyperuricemia prevalence rates are 20.2% in men and 20.0% in women [10]. In the Chinese rural population, the total estimated prevalence of hyperuricemia is 10.24% (12.80% in men and 8.56% in women) [11]. In the general Korean population, the age-standardized prevalence of hyperuricemia is 11.4% (17.0% in men and 5.9% in women) [12]. The progressive increase of hyperuricemia worldwide may be linked to the rising prevalence of overweight and obesity and increased consumption of sugar-sweetened beverages, foods rich in purines, and alcohol [13].

As hyperuricemia results from increased production and decreased excretion, or both, of UA [14], it is crucial to prevent and treat the disorder to regulate the SUA level. UA is produced by xanthine oxidase (XOD), a rate-limiting enzyme that oxidizes hypoxanthine to xanthine, which is subsequently converted to UA [15]. Hence, SUA synthesis and concentration can be affected by XOD enzymatic activity [16]. Therefore, proteins involved in UA production and transport in the kidney may act as important drug targets for treating hyperuricemia.

XOD inhibitors (allopurinol (ALP) and febuxostat) and uricosuric agents (benzbromarone and probenecid) are presently used [17] to clinically treat hyperuricemia. However, these drugs are poorly tolerated and cause side effects, such as kidney diseases, hepatotoxicity, gastrointestinal symptoms, and hypersensitivity syndrome [18]. Therefore, more effective therapeutic agents for hyperuricemia with no adverse effects are needed. In previous studies, new therapeutic methods using herbs were offered to overcome these limitations of drugs for hyperuricemia [19].

Dendropanax morbifera H. Lév. (DM) is an evergreen broad-leaved tree of the Araliaceae family and is well known as a panacea and wild ginseng tree [9]. DM is an endemic species in Korea and is distributed in the country’s southern regions [20]. In previous studies, extracts from roots and stems of DM have antioxidant [21], antibacterial [20], anticancer [22], antidiabetic [23], antiobesitic [9], antihyperglycemic [24], and antiatherogenic [25] properties. DM contains various bioactive compounds, such as triterpenoids, polyacetylene, phenolic substances, _L-arginine, and γ-aminobutyric acid (GABA) [26]. _L-Arginine is a substrate of nitric oxide (NO) synthesis by NO synthase in almost all cell types. NO regulates glucose metabolism, fatty acids, and amino acids in mammals [27]. Additionally, GABA plays an essential physiological role in regulating cardiovascular function.

Therefore, in this study, the antioxidant and xanthine oxidase (XOD)-inhibitory activity of DM leaves (DML) was evaluated using different solvent extraction conditions (hot water and 30%, 50%, and 70% ethanol). Additionally, the antihyperuricemic effects of DML extracts were investigated in a potassium oxonate (PO)-induced hyperuricemia rat model, and the detailed mechanisms were explored.

2. Materials and Methods

2.1. Plant Extracts

DML was provided by Hyurim Hwangchil Co., Ltd. (Jinju, Korea), and dried in a shade, crushed, and stored in a refrigerator. The extracts were prepared as described by Kim et al. (2016) with some modifications. Approximately 100 g of the plant powder was extracted with 500 mL of water and 30%, 50%, and 70% ethanol solution for 2 h at 80°C. Subsequently, the solvent was evaporated using a rotary vacuum evaporator at 40°C, freeze-dried, and weighted. Following the method above, the extraction was performed in triplicate for each solvent. The freeze-dried powders of DML ethanol extracts were named DMLEs and stored at 4°C until use.

2.2. Analysis of Chlorogenic Acid and Rutin Concentrations in DMLEs

The qualitative and quantitative analyses of chlorogenic acid (CGA) and rutin in DMLEs were conducted using an LC-MS 8050 chromatography system (Shimadzu, Kyoto, Japan) composed of a binary solvent delivery system (LC-30 AD), a controller (CBM 20A), an autosampler (SIL-30A), and a column thermostat (CTO-20AC). Tandem mass spectrometry (MS/MS) analysis was performed positively and negatively on a triple quadrupole equipped with a positive electrospray ionization (+ESI) source. The optimal parameters of ESI-MS were as follows: interface temperature of 340°C, DL temperature of 200°C, nebulizing gas flow at 2.8 L/min, heating gas flow at 8 L/min, and temperature of drying gas at 400°C. The active biological compounds were monitored using a scheduled multiple reaction monitoring mode and separated using a Kinetex C18 column (150 × 2.1 mm, 2.6 µm; Phenomenex, Torrance, CA, USA) at a flow rate of 0.3 mL/min, injection volume of 2 µL, and separation temperature of 40°C. The mobile phase consisted of water containing 5 mM ammonium acetate and 0.1% formic acid (A) and methanol containing 2.5 mM ammonium acetate (B) (gradient 0–18 min; 5%–100% B).

2.3. 2,2-Diphenyl-1-picryl-hydrazyl (DPPH) Radical Scavenging Assay

The 2,2-diphenyl-1-picryl-hydrazyl (DPPH) radical scavenging assay was conducted following the description by Okoh et al. using vitamin C as the positive control [28]. Here, 0.1 mL of 0.135 mM DPPH in methanol was mixed with 1.0 mL of the solution prepared in methanol containing 0.025–0.50 mg/mL of DMLEs, CGA, rutin, and vitamin C. The reaction mixture was vortexed thoroughly, left in the dark at 25°C for 30 min, and measured at 517 nm using a spectrophotometer. The DPPH radical scavenging effect was calculated using the equation below: Here, A_c is the absorbance of the control reacted with methanol (50 μL) and DPPH working solution (1 mL); and A_s is the absorbance of the samples.

The sample concentration required for inhibiting 50% DPPH radicals (IC₅₀ DPPH values) was obtained by extrapolating the regression analysis. Antioxidant activity was evaluated based on this IC₅₀ value.

2.4. Measurement of Reactive Oxygen Species (ROS) Production

The acute myelogenous leukemia cell line OCI-AML-2 line from the Ontario Cancer Institute (Toronto, Canada) was cultured at 37°C in a 5% CO₂ atmosphere using minimum essential medium alpha (α-MEM) (Gibco BRL, Grand Island, NY, USA) with 10% heat-inactivated fetal bovine serum. The drug-resistant AML-2 sublines were selected from a parental cell line (AML-2/WT) after chronic exposure to doxorubicin. The cells were finally cultured in a fixed concentration (100 ng/mL) of doxorubicin. The AML-2/DX100 cells were characterized by catalase downregulation and used to determine antioxidant effects [29]. The cells were seeded onto 96-well plates at a density of 1.5 × 10⁴ cells per well in 100 μL of growth media. At 50% confluence, cells were then loaded with 10 μM 2′,7′-dichlorofluorescein diacetate (DCFH-DA; Sigma, St. Louis, MO) and 4 mM hydrogen peroxide (H₂O₂; Sigma, St. Louis, MO) in Hanks’ balanced salt solution (HBSS; Gibco, Grand Island, NY, USA) at 37°C for 30 min. After loading, cells were washed twice with 200 μL of HBSS to remove excess fluorescent dye. Cells were then treated with 50 and 100 µg/mL of DMLEs, CGA, rutin, and vitamin C and washed twice with 200 μL of HBSS, and 100 μL of HBSS/well was added. The fluorescence intensity of DCFH-DA was measured at an excitation wavelength of 485 nm and an emission wavelength of 520 nm. Cells treated with H₂O₂ without DMLEs, CGA, rutin, and vitamin C were the controls. The measured fluorescence values were expressed as a percentage of the control.

2.5. Determination of XOD-Inhibitory Activity

The inhibitory effect on XOD was spectrophotometrically determined according to a method by Arimboor et al. with some modifications [30]. Briefly, 0.7 mL of 0.2 XOD unit in sodium phosphate buffer (0.1 M; pH 7.5) and 0.1 mL of various concentrations of DMLEs (0.1–5.0 mg/mL), CGA, rutin, and ALP were mixed at 37°C for 5 min. The control did not contain test agents. After 5 min, 0.2 mL of 2 mM xanthine in distilled water was added to the mixture. Each mixture was shaken at 37°C for 15 min, and 1 mL of a stop buffer (1 N HCl) was added. ALP was used as a positive control. The absorbance of the mixture was measured at 290 nm using an ultraviolet-visible (UV-VIS) spectrophotometer (Optizen POP; CM Science, Busan, Korea). The IC₅₀ values of the test samples and compounds were obtained using GraphPad Prism v.5.0 (GraphPad Software, Inc.).

2.6. Cell Cytotoxicity Assay

The human hepatocellular carcinoma cell line Hep3B (ATCC HB-8064) was grown in Dulbecco’s modified Eagle’s medium (DMEM; Merck KGaA, Darmstadt, Germany) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C under 5% CO₂. Cell viability assay was examined following the procedure described earlier [20]. Briefly, cells (5 × 10³ cells/well) were plated onto a 96-well plate and cultured for 24 h at 37°C under 5% CO₂. After 24 h, the cells were treated with various concentrations of DMLEs and incubated for 72 h. After 72 h, cells were washed with PBS, and 20 µL of 3-(4,5-dimethylthiazol 2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/mL) was added to each well. After incubation for 4 h, dimethyl sulfoxide (DMSO) was added to dissolve formazan crystals from MTT reduction, and the amount of formazan salt was determined by measuring the optical density at 540 nm using an ELISA plate reader (Bio-Rad, Hercules, CA, USA). By comparing the absorbance of the wells of cells treated with different concentrations of DMLEs with the control, the viability of cells after treatment with DMLEs was calculated. The concentration of DMLEs that reduced the cell viability by 50% (IC₅₀) was recorded.

2.7. Animals

Sixty Sprague-Dawley rats (male, 5 weeks, 110–150 g) were purchased from Orient Bio (Seongnam, Korea) and randomly distributed into different experimental groups. The rats were housed in polypropylene cages at an ambient temperature of 25°C ± 1°C and 45%–55% relative humidity, with a 12 : 12-h light/dark cycle. Animals were provided with commercial food pellets and water ad libitum, unless stated otherwise. They were acclimatized to laboratory conditions for at least 1 week before experimenting on them. The experimental design was approved by the Institutional Animal Care and Use Committee of KemOn Inc. (Suwon, Korea) (Approval No. 2019-10-001), and all experiments were performed according to the guidelines established by the committee.

2.8. Induction of Hyperuricemia and Experimental Design

After acclimation for 7 d, the uricase inhibitor PO was intraperitoneally injected into rats to induce hyperuricemia. To study the antihyperuricemic effects of the 70% ethanol extract from DML (DMLE-70), the rats were randomly divided into six groups (n = 8 per group): (1) a normal control group (NC), (2) a PO-induced hyperuricemia model group (PC), (3) a PC + 50 mg/kg ALP group (ALT), (4) a PC + 50 mg/kg DMLE-70 group (DMEE-50), (5) a PC + 100 mg/kg DMLE-70 group (DMEE-100), and (6) a PC + 200 mg/kg DMLE-70 group (DMEE-200). Rats in all groups, except for NC, were injected intraperitoneally with 250 mg/kg PO prepared in 0.5% carboxymethylcellulose (CMC) with 0.1 M sodium acetate (pH 5.0) at 1, 3, 5, and 7 d after acclimation, and NC was treated with 0.5% CMC with 0.1 M sodium acetate. Rats of all groups, except for NC and PC, were administered extract once a day for 7 d from 1 h after the first injection of PO. The animals were anesthetized using isoflurane and sacrificed for sample collection.

2.9. Sample Collection and Analysis

Urine samples were collected during a 2-h period using a metabolic cage following the last substance administration. The volume of urine collected was 4–6 mL, and there was no difference in urine volume among the treated group. The samples were then centrifuged (3000 × g for 10 min at 4°C) to remove particulate contaminants, and the supernatants were stored at −80°C until analysis. After collecting urine samples, blood samples were collected via cardiac puncture and centrifuged (3000 × g for 10 min at 4°C) to obtain serum. The separated serum was stored at −80°C until analysis. According to the manufacturer’s instructions, serum and urine levels of UA were determined using commercial assay kits (BioVision, Milpitas, CA, USA). At the end of the experiment, rats were euthanized by cervical dislocation after taking blood, and the liver tissue was collected and preserved at −20°C to determine the XOD activity.

2.10. Statistical Analyses

Data are expressed as the mean ± SEM. Statistical comparisons were analyzed by one-way analysis of variance (ANOVA) and Student's t-test using SPSS v.13.0. A p-value less than 0.05 was considered statistically significant.

3. Results

3.1. Extraction Yield

As a result of comparing the yield of DMLEs by the solvents, the yield of hot water extracts was highest at 24.14%, and the extraction yield decreased as the ethanol content increased (30% ethanol, 23.24%; 50% ethanol, 21.02%; and 70% ethanol, 19.66%).

3.2. Analysis of Chlorogenic Acid and Rutin Concentrations

Typical chromatograms of CGA and rutin are shown in Figure 1, representing the selected reaction monitoring chromatograms with a mass transition of CGA (m/z 355.00 ⟶ 145.15) and rutin (m/z 615.00 ⟶ 465.10). No interference peaks were detected at the retention times of all analytes. CGA and rutin were eluted at retention times of 11.321 and 13.502 min, respectively. In the LC-ESI-MS/MS analysis results, the concentrations of CGA and rutin increased depending on the ethanol concentration, and 70% DML ethanol extract (DMLE-70) had the highest CGA and rutin concentrations (Table 1).

(A)

(B)

3.3. Antioxidant Activity

DPPH radical scavenging activities were analyzed to determine the antioxidant activity of DMLEs. IC₅₀ represents DPPH radical scavenging activities, and vitamin C was used as a positive control (Table 2). The IC₅₀ of CGA was significantly low compared with that of DMLEs and rutin (). However, no significant difference in IC₅₀ was observed between CGA and vitamin C. The IC₅₀ of DMLE-70 was the most active among the DMLEs.

3.4. Measurement of ROS Production

The DCFH-DA assay was performed to evaluate the intracellular ROS scavenging activity of DMLEs and their active compounds in H₂O₂-treated AML-2/DX100 cells. After 400 µM H₂O₂ treatment, ROS scavenging activity was not significant among DMLEs, CGA, rutin, and vitamin C at a 50 µg/mL concentration. For treatment with 100 µg/mL of DMLEs or compounds, the 50% ethanol extract showed the strongest ROS scavenging activity. There was no significant difference between the ROS scavenging activity of the water extract and DMLE-30. By contrast, there was a significant difference among all test materials, except for DMLE-30 and DMLE-70 () (Table 3).

3.5. Determination of XOD-Inhibitory Activity

DMLEs and compounds of the XOD-inhibitory activity are shown in Table 4. The IC₅₀ of ALP was 50 µg/mL, which was the lowest among the test substances, followed by CGA. In addition, the IC₅₀ of DMLE-70 was significantly low compared with that of other DMLEs (). However, the IC₅₀ of rutin was more than 1000 µg/mL, and there was almost no XOD-inhibitory activity.

3.6. Cell Cytotoxicity

In the MTT assay results, the IC₅₀ values of DMLEs were more than 1.11 mg/mL (Table 5). The IC₅₀ value of DMLW (2.08 mg/mL) was significantly high compared with that of other DMLEs (). In the ethanol extracts, the IC₅₀ value decreased with an increase in the percentage of ethanol in the extraction solvents. However, no statistically significant difference was observed between each ethanol extract. Therefore, it was confirmed that the IC₅₀ values of all DMLEs were more than 1.11 mg/mL, indicating almost no cytotoxicity.

3.7. UA Levels in Serum and Urine in the Hyperuricemic Rat Model

The PC group exhibited significantly higher UA levels in serum and urine than the NC group did (), indicating that hyperuricemia was effectively established. UA levels in serum and urine were significantly reduced in all DMLE-70 and ALT groups compared with the PC group () (Figure 2). In all DME groups, UA levels in urine were lower than those in serum. In PO-induced hyperuricemic rats, DMEE-200 reduced UA concentration in serum and increased UA excretion through the urine.

Figure 2

Effects of 70% ethanol extracts from Dendropanax morbifera leaf (DMLE-70) on serum (■) and urine uric acid (□) levels in rats with potassium oxonate-induced hyperuricemia. NC, normal control group; PC, PO-induced hyperuricemia model group; DMEE-50, PC + 50 mg/kg DMLE-70 group; DMEE-100, PC + 100 mg/kg DMLE-70 group; DMEE-200, PC + 200 mg/kg DMLE-70 group; ALT, PC + 50 mg/kg allopurinol group. , significantly different from PC, . a, b, c, d: Mean values with different superscript letters in the same row show significant differences at by one-way ANOVA.

3.8. XOD Activity in Serum and Liver Tissue

XOD activity in serum showed no significant differences between all groups, except for the ALT group (Table 6). There was no significant difference in hepatic XOD activity between the PO-induced hyperuricemic rat group (PC) and the groups treated with DMLE-70 at concentrations of 50 and 100 mg/kg. However, hepatic XOD activity in the PC group was significantly increased compared with that in the group treated with DMLE-70 at a 200 mg/kg () concentration. Meanwhile, treatment with ALP significantly reduced XOD activity in serum and liver tissue compared with that in all groups ().

4. Discussion

Hyperuricemia is a metabolic disorder characterized by a high UA level in serum due to an imbalance between UA production and excretion and causes gout [14]. Recently, the prevalence of hyperuricemia has continuously increased worldwide [31]. Currently, there are a limited number of drugs available for treating hyperuricemia, and many of these drugs have side effects.

Among the uricosuric agents, benzbromarone has been discontinued since 2003 because of severe hepatotoxicity reported in most European countries [32]. Although ALP belonging to XO inhibitors has been mainly used to treat hyperuricemia, this drug has been associated with severe cutaneous adverse reactions [33]. Therefore, many previous studies have been conducted to develop safe therapeutic agents using natural products for hyperuricemia without side effects [14, 19, 30].

This study showed the antioxidant, XOD-inhibitory, and antihyperuricemic activities of DMLEs and determined active components. The upregulation of XOD expression and activity increases reactive oxygen species (ROS) production. The XOD activity produces superoxide anions that can rapidly respond with nitric oxide to form the cytotoxic oxidant leading to various diseases including endothelial dysfunction and cardiovascular diseases [34]. When the local levels of ROS are increasing, they cause considerable cellular damage and generate other more reactive radicals [35]. As regards the production of ROS by XO, under conditions of oxidative stress, XO activity prevails to XDH activity, resulting in further ROS production. In cultures of endothelial cells, NOX maintains XO levels and XO is responsible for increased ROS production [36]. In this study, DMLE-70 had the strongest DPPH free radical scavenging activity and XOD-inhibitory activity among the DMLEs (Tables 2–4). These findings suggest that DMLEs inhibit hyperuricemia by inhibiting the generation of ROS through its XOD-inhibitory effect. However, DMLE-50 showed the strongest ROS scavenging activity at a 100 µg/mL concentration among the DMLEs. On the basis of these results, DMLE-70 was selected for further in vivo experiments.

In the LC-MS/MS analysis results, DMLE-70 had the highest CGA and rutin concentrations (Table 1). CGA is an abundant polyphenol in human diet and Chinese medicines and possesses extensive pharmacological antimicrobial, antioxidant, anti-inflammatory, protection of cardiovascular and cerebrovascular system [37], and antigout activities [38]. Rutin is an essential flavonoid in herbal foods, which significantly reduced SUA levels in mice with hyperuricemia [39] and increased urinary UA concentration in rats with renal dysfunction [40]. In a previous study [41], the CGA and rutin contents from DML extracts in 70% ethanol for 2 h were the highest at 12.33 and 14.09 mg/g, respectively. In another study, the CGA concentration in the 30% DML ethanol extract collected in November was the highest at 36.55 mg/g, and the rutin content in the 60% DML ethanol extract collected in May was the highest at 116.71 mg/g [42]. In this study, the concentrations of CGA and rutin were approximately 0.5 and 0.25 times lower than those of Youn et al. but twice as high as those of Hwang et al. [41] (Table 1). This showed that the difference in CGA content and rutin depends on the harvesting location, season, and extraction conditions of DML [42].

We investigated whether DMLE extract showed antihyperuricemic effects in PO-induced hyperuricemic rats. In this study, DMEE-50, 100, and 200 significantly decreased serum UA levels compared with the PC group (). Additionally, DMEE-50 and 100 reduced UA levels in urine compared with the PC group (). Meanwhile, the urine UA levels of DMEE-200 were higher than those of DMEE-50 and 100, although there were no significant differences in urine UA levels between DMEE-200 and DMEE-50 and 100. These results suggest that DMEE-200 alleviates hyperuricemia by decreasing the UA concentration in the blood and increasing UA excretion in the urine (Figure 2).

Additionally, we demonstrated that DMLE could decrease serum UA levels in PO-induced hyperuricemic mice by inhibiting hepatic XOD activity. Inhibiting XOD activity in the liver reduces UA production and enhances UA excretion [43, 44]. DMLE-70 at all doses did not exhibit potent hypouricemic effects in serum compared with PC, but inhibiting hepatic XOD activity was significantly effective with DMEE-200 compared with the PC (Table 6), although the amount of uric acid excreted in urine was decreased compared with PC. These results elucidated that the hypouricemic effect of DMLE is caused by inhibiting XOD, which is a crucial enzyme in the biosynthetic pathway of UA. The effect of DMLE on renal transporters, which contribute to UA reabsorption, is unknown and will be the focus of our subsequent study.

This study demonstrated that DMLE reduced serum UA levels and enhanced the excretion of UA in rats with PO-induced hyperuricemia. DMLE has an antioxidant activity in vitro and inhibits XO activity of the liver and serum in vivo, thus preventing hyperuricemia. This study elucidates that DMLE exhibits beneficial effects and may be potentially helpful in treating hyperuricemia and gout.

Data Availability

The data are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflicts of interest to declare with regard to the manuscript.

Authors’ Contributions

KI Park conceived and designed the study and supported all materials. DH Lee and JK Kim performed the experiments, treatments/animal care, and statistical analysis. YJ Han wrote the manuscript. KI Park reviewed the literature, revised the manuscript, and coordinated the study. DH Lee and JK Kim equally contributed to this work.

References

S.-K. Kim, “Interrelationship of uric acid, gout, and metabolic syndrome: focus on hypertension, cardiovascular disease, and insulin resistance,” Journal of Rheumatic Diseases, vol. 25, no. 1, pp. 19–27, 2018.
View at: Publisher Site | Google Scholar
Q. Ni, X. Lu, C. Chen, H. Du, and R. Zhang, “Risk factors for the development of hyperuricemia: a STROBE-compliant cross-sectional and longitudinal study,” Medicine, vol. 98, no. 42, p. e17597, 2019.
View at: Publisher Site | Google Scholar
G. Glantzounis, E. Tsimoyiannis, A. Kappas, and D. Galaris, “Uric acid and oxidative stress,” Current Pharmaceutical Design, vol. 11, no. 32, pp. 4145–4151, 2005.
View at: Publisher Site | Google Scholar
E. S. Perez, M. A. G. Medina, M. L. Lomeli et al., “Association between serum uric acid and metabolic syndrome components in prepubertal obese children (tanner stage I) from Nuevo Leon, Mexico-a preliminary study,” BMC Obesity, vol. 4, no. 25, 2017.
View at: Publisher Site | Google Scholar
I. A. Bobulescu and O. W. Moe, “Renal transport of uric acid: evolving concepts and uncertainties,” Advances in Chronic Kidney Disease, vol. 19, no. 6, pp. 358–371, 2012.
View at: Publisher Site | Google Scholar
D. J. Stewart, V. Langlois, and D. Noone, “Hyperuricemia and hypertension: links and risks,” Integrated Blood Pressure Control, vol. 12, pp. 43–62, 2019.
View at: Publisher Site | Google Scholar
A. F. G. Cicero, M. Rosticci, M. Bove et al., “Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study,” Annals of Medicine, vol. 49, no. 4, pp. 275–282, 2017.
View at: Publisher Site | Google Scholar
T. Katova, I. Simova, Y. Yotov, K. Peeva, and N. Georgieva, “Hyperuricemia and cardiovascular risk in the Bulgarian population,” Cureus, vol. 1, p. 101, 2020.
View at: Google Scholar
P. Song, H. Wang, W. Xia, X. Chang, M. Wang, and L. An, “Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China,” Scientific Reports, vol. 8, p. 4314, 2018.
View at: Publisher Site | Google Scholar
M. Chen-Xu, C. Yokose, S. K. Rai, M. H. Pillinger, and H. K. Choi, “Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016,” Arthritis & Rheumatology, vol. 71, no. 6, pp. 991–999, 2019.
View at: Google Scholar
X. Dong, H. Zhang, F. Wang et al., “Epidemiology and prevalence of hyperuricemia among men and women in Chinese rural population: the Henan rural cohort study,” Modern Rheumatology, vol. 30, no. 5, pp. 910–920, 2020.
View at: Publisher Site | Google Scholar
Y. Kim, J. Kang, and G.-T. Kim, “Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample,” Clinical Rheumatology, vol. 37, no. 9, pp. 2529–2538, 2018.
View at: Publisher Site | Google Scholar
G. Desideri, J. G. Puig, and P. Richette, “The management of hyperuricemia with urate deposition,” Current Medical Research and Opinion, vol. 31, no. 2, pp. 27–32, 2015.
View at: Publisher Site | Google Scholar
Y. S. Lee, E. Son, S. H. Kim, Y. M. Lee, O. S. Kim, and D. S. Kim, “Synergistic uric acid-lowering effects of the combination of Chrysanthemum indicum linne flower and cinnamomum cassia (L.) J. Persl bark extracts,” Evidence-based Complementary and Alternative Medicine: ECAM, vol. 2017, Article ID 9764843, 9 pages, 2017.
View at: Publisher Site | Google Scholar
Y. Zhang, L. Jin, J. Liu et al., “Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia,” Journal of Ethnopharmacology, vol. 214, pp. 29–36, 2018.
View at: Publisher Site | Google Scholar
L.-L. Kang, D.-M. Zhang, C.-H. Ma et al., “Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation,” Scientific Reports, vol. 6, no. 1, p. 27460, 2016.
View at: Publisher Site | Google Scholar
D.-R. Oh, J. R. Kim, C. Y. Choi et al., “Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1,” BMC Complementary and Alternative Medicine, vol. 19, no. 1, p. 10, 2019.
View at: Publisher Site | Google Scholar
R.-J. Chen, M.-H. Chen, Y.-L. Chen et al., “Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study,” Journal of Food and Drug Analysis, vol. 25, no. 3, pp. 597–606, 2017.
View at: Publisher Site | Google Scholar
R. Bao, M. Liu, D. Wang et al., “Effect of eurycoma longifolia stem extract on uric acid excretion in hyperuricemia mice,” Frontiers in Pharmacology, vol. 10, p. 1464, 2019.
View at: Publisher Site | Google Scholar
R.-W. Kim, S.-Y. Lee, S.-G. Kim, Y.-R. Heo, and M.-K. Son, “Antimicrobial, antioxidant and cytotoxic activities of Dendropanax morbifera Léveille extract for mouthwash and denture cleaning solution,” The Journal of Advanced Prosthodontics, vol. 8, no. 3, pp. 172–180, 2016.
View at: Publisher Site | Google Scholar
W. Kim, D. W. Kim, D. Y. Yoo et al., “Antioxidant effects of Dendropanax morbifera Leveille extract in the hippocampus of mercury-exposed rats,” BMC Complementary and Alternative Medicine, vol. 15, 2015.
View at: Publisher Site | Google Scholar
T. K. Hyun, M.-o. Kim, H. Lee, Y. Kim, E. Kim, and J.-S. Kim, “Evaluation of anti-oxidant and anti-cancer properties of Dendropanax morbifera Léveille,” Food Chemistry, vol. 141, no. 3, pp. 1947–1955, 2013.
View at: Publisher Site | Google Scholar
H.-I. Moon, “Antidiabetic effects of dendropanoxide from leaves of Dendropanax morbifera Leveille in normal and streptozotocin-induced diabetic rats,” Human & Experimental Toxicology, vol. 30, no. 8, pp. 870–875, 2011.
View at: Publisher Site | Google Scholar
X. Tan and H. K. Ryu, “Effects of Dendropanax morbifera leaf extracts on lipid profiles in mice fed a high-fat and high-cholesterol diet,” Journal of the Korean Society of Food Science and Nutrition, vol. 44, no. 5, pp. 641–648, 2015.
View at: Publisher Site | Google Scholar
I. M. Chung, M. Y. Kim, W. H. Park, and H. I. Moon, “Antiatherogenic activity of Dendropanax morbifera essential oil in rats,” Die Pharmazie, vol. 64, no. 8, pp. 547–549, 2009.
View at: Google Scholar
E. J. Rupa, L. Arunkumar, Y. Han et al., “Dendropanax morbifera extract-mediated ZnO nanoparticles loaded with indole-3-carbinol for enhancement of anticancer efficacy in the A549 human lung carcinoma cell line,” Materials (Basel, Switzerland), vol. 13, no. 14, 2020.
View at: Publisher Site | Google Scholar
S. Park, K. H. Lee, W. S. Kang, J. S. Kim, and S. Kim, “Endothelium-dependent and endothelium-independent vasorelaxant effects of unripe Rubus coreanus Miq. and Dendropanax morbiferus H. Lév. extracts on rat aortic rings,” BMC Complementary Medicine and Therapies, vol. 20, no. 1, p. 190, 2020.
View at: Publisher Site | Google Scholar
S. Okoh, O. Asekun, O. Familoni, and A. Afolayan, “Antioxidant and free radical scavenging capacity of seed and shell essential oils extracted from Abrus precatorius (L),” Antioxidants, vol. 3, no. 2, pp. 278–287, 2014.
View at: Publisher Site | Google Scholar
J.-M. Jeong, C.-H. Choi, S.-K. Kang, I.-H. Lee, J.-Y. Lee, and H. Jung, “Antioxidant and chemosensitizing effects of flavonoids with hydroxy and/or methoxy groups and structure-activity relationship,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 10, no. 4, pp. 537–546, 2007.
View at: Publisher Site | Google Scholar
R. Arimboor, M. Rangan, S. G. Aravind, and C. Arumughan, “Tetrahydroamentoflavone (THA) from Semecarpus anacardium as a potent inhibitor of xanthine oxidase,” Journal of Ethnopharmacology, vol. 133, no. 3, pp. 1117–1120, 2011.
View at: Publisher Site | Google Scholar
E. Zitt, A. Fischer, K. Lhotta, H. Concin, and G. Nagel, “Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort,” Scientific Reports, vol. 10, no. 1, p. 7578, 2020.
View at: Publisher Site | Google Scholar
T. L. Jansen, M. K. Reinders, E. N. Van Roon, and J. R. Brouwers, “Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”?” Clinical and Experimental Rheumatology, vol. 22, no. 5, p. 651, 2004.
View at: Google Scholar
S. N. Ramasamy, C. S. Korb-Wells, D. R. Kannangara et al., “Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012,” Drug Safety, vol. 36, no. 10, pp. 953–980, 2013.
View at: Google Scholar
M. Gliozzi, N. Malara, S. Muscoli, and V. Mollace, “The treatment of hyperuricemia,” International Journal of Cardiology, vol. 213, pp. 23–27, 2013.
View at: Google Scholar
C. E. Berry and J. M. Hare, “Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications,” The Journal of Physiology, vol. 555, no. Pt 3, pp. 589–606, 2004.
View at: Publisher Site | Google Scholar
N. Liu, H. Xu, Q. Sun et al., “The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 1470380, 15 pages, 2021.
View at: Publisher Site | Google Scholar
L.-M. Liu, S.-F. Cheng, P.-C. Shieh et al., “The methanol extract of Euonymus laxiflorus, Rubia lanceolata and Gardenia jasminoides inhibits xanthine oxidase and reduce serum uric acid level in rats,” Food and Chemical Toxicology, vol. 70, pp. 179–184, 2014.
View at: Publisher Site | Google Scholar
Z. Q. Meng, Z. H. Tang, Y. X. Yan et al., “Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation,” The American Journal of Chinese Medicine, vol. 42, no. 6, pp. 1471–1483, 2014.
View at: Publisher Site | Google Scholar
Y. S. Chen, Q. H. Hu, X. Zhang, Q. Zhu, and L. D. Kong, “Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice,” Pharmacology, vol. 92, no. 1-2, pp. 75–83, 2013.
View at: Publisher Site | Google Scholar
Q.-H. Hu, C. Wang, J.-M. Li, D.-M. Zhang, and L.-D. Kong, “Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement,” American Journal of Physiology-Renal Physiology, vol. 297, no. 4, pp. F1080–F1091, 2009.
View at: Publisher Site | Google Scholar
C. E. Hwang, S. C. Kim, C. S. Cho, W. Y. Song, O. S. Joo, and K. M. Cho, “Comparison of chlorogenic acid and rutin contents and antioxidant activity of Dendropanax morbiferus extracts according to ethanol concentration,” Korean Journal of Food Preservation, vol. 27, no. 7, pp. 880–887, 2020.
View at: Publisher Site | Google Scholar
J. S. Youn, Y.-J. Kim, H. J. Na et al., “Antioxidant activity and contents of leaf extracts obtained from Dendropanax morbifera LEV are dependent on the collecting season and extraction conditions,” Food Science and Biotechnology, vol. 28, no. 1, pp. 201–207, 2019.
View at: Publisher Site | Google Scholar
Y. Chen, Z. Zhao, Y. Li et al., “Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase,” Phytomedicine, vol. 80, Article ID 153374, 2021.
View at: Publisher Site | Google Scholar
L. L. Jiang, X. Gong, M. Y. Ji, C. C. Wang, J. H. Wang, and M. H. Li, “Bioactive compounds from plant-based functional foods: a promising choice for the prevention and management of hyperuricemia,” Foods (Basel, Switzerland), vol. 9, no. 8, 2020.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2021 Dongho Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies